Nonalcoholic steatohepatitis increases plasma retention of sorafenib-glucuronide in a mouse model by altering hepatocyte hopping
-
Published:2024-09
Issue:
Volume:
Page:
-
ISSN:2211-3835
-
Container-title:Acta Pharmaceutica Sinica B
-
language:en
-
Short-container-title:Acta Pharmaceutica Sinica B
Author:
Toth Erica,
Li Hui,
Frost KaylaORCID,
Sample Paxton,
Jilek JosephORCID,
Greenfield SiennahORCID,
You Dahea,
Kozlosky DanielleORCID,
Goedken Michael,
Paine Mary F.,
Aleksunes LaurenORCID,
Cherrington Nathan
Reference36 articles.
1. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis;Marra;Trends Mol Med,2008
2. Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016
3. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease;Lake;Drug Metab Dispos,2011
4. Adverse drug events in the outpatient setting: an 11‐year national analysis;Bourgeois;Pharmacoepidemiol Drug Saf,2010
5. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events;Rimola;Hepatology,2018